Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Pharming Group N.V. is a commercial-stage biopharmaceutical company focused on developing, manufacturing, and commercializing treatments for rare diseases and unmet medical needs. The company operates within the biotechnology and rare disease pharmaceutical industries, with revenues primarily derived from specialty therapeutics targeting small patient populations with high unmet need.
The company’s core business centers on the discovery and commercialization of biologic medicines, with a particular emphasis on protein replacement therapies and novel immunological treatments. Pharming’s strategic positioning is supported by its proprietary transgenic production technology and its established commercial infrastructure in rare diseases. Founded in 1988 in the Netherlands, Pharming initially focused on transgenic animal platforms for protein production and evolved into a fully integrated biopharmaceutical company following regulatory approvals and the commercial success of its lead product in the 2010s.
Business Operations
Pharming generates revenue primarily through the commercialization of RUCONEST®, a recombinant human C1 esterase inhibitor approved for the treatment of acute hereditary angioedema (HAE) attacks. The company operates through a single reportable segment focused on rare disease therapeutics, encompassing research and development, manufacturing, regulatory affairs, and global commercialization.
Operations span both domestic and international markets, with direct commercial activities in North America and Europe, and distribution partnerships supporting access in other regions. Pharming controls proprietary recombinant protein production technology using transgenic animal systems and maintains internal capabilities across clinical development and medical affairs. The company operates through key subsidiaries, including Pharming Technologies B.V. and Pharming Healthcare, Inc., which support manufacturing, R&D, and U.S. commercial operations.
Strategic Position & Investments
Pharming’s strategy centers on expanding its rare disease portfolio through internal development and selective acquisitions that leverage its existing commercial infrastructure. A key strategic milestone was the acquisition of Abliva AB, which expanded Pharming’s pipeline into mitochondrial diseases and reinforced its long-term growth strategy beyond HAE.
The company is investing in late-stage and early-stage clinical programs targeting rare and ultra-rare indications, including immune and metabolic disorders. Pharming continues to prioritize lifecycle management of RUCONEST® while advancing new assets intended to diversify revenue sources and reduce product concentration risk. Its strategic focus emphasizes regulatory-driven markets with orphan drug protections and premium pricing dynamics.
Geographic Footprint
Pharming Group N.V. is headquartered in Leiden, Netherlands, and maintains a strong operational presence in North America through its U.S. subsidiary. The United States represents the company’s largest commercial market and primary revenue contributor.
Beyond Europe and North America, Pharming has a commercial and distribution footprint extending into parts of Asia-Pacific, Latin America, and the Middle East through regional partners. While the company’s physical operations are concentrated in Europe and the U.S., its products are marketed across multiple continents, reflecting its international regulatory approvals and global rare disease strategy.
Leadership & Governance
Pharming is led by an experienced executive team with backgrounds in biotechnology, rare diseases, and global pharmaceuticals. The leadership emphasizes disciplined capital allocation, patient-focused innovation, and long-term value creation through sustainable rare disease franchises.
Key executives include:
- Fabrice Chouraqui – Chief Executive Officer
- Sijmen de Vries – Chief Strategy Officer
- Jorn Aldag – Chairman of the Board
- Monique Kramer – Chief Financial Officer
- Anurag Relan – Chief Medical Officer
The company operates under a Dutch corporate governance framework, with oversight by a supervisory board and compliance with international regulatory and reporting standards applicable to publicly listed biopharmaceutical companies.